DNA Methylation Profiling for Carcinoma of Unknown Primary Origin Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying the origin of carcinomas of unknown primary origin (CUP) are limited in specificity and accuracy, with existing diagnostic techniques such as serum tumor markers, immunohistochemical methods, and imaging technologies only resolving 20-30% of cases ante mortem, and gene expression profiling facing challenges with RNA degradation in formalin-fixed, paraffin-embedded tissues.
Innovation Solution
A method involving DNA methylation profiling by determining and comparing the methylation status of specific CpG sites in CUP samples with primary tumors to identify the origin, using techniques like bisulfite treatment, methylation-specific PCR, and pyrosequencing to provide a substantial identity indicative of the tumor origin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gene expression profiling is used to identify tumor origin, then diagnostic accuracy can be improved, but the method fails when RNA is degraded in formalin-fixed, paraffin-embedded tissues
Solution Approach 1:
The patent changes the molecular parameter from RNA-based gene expression to DNA-based methylation analysis. DNA is more stable than RNA and remains intact in formalin-fixed, paraffin-embedded tissues, allowing methylation profiling to be performed on routine clinical specimens without requiring fresh or frozen tissue samples.
Solution Approach 2:
The patent replaces the RNA-based gene expression profiling mechanism with a DNA-based methylation analysis mechanism. This substitution uses different molecular biology principles (methylation status detection via bisulfite conversion and PCR) that are more robust to tissue fixation and storage conditions.
2Measurement precision
If multiple IHC markers are used to identify tumor lineage, then diagnostic accuracy improves to 66-88%, but the complexity of the diagnostic panel increases
Solution Approach 1:
The patent extracts the diagnostic information from multiple protein markers and consolidates it into a single DNA methylation profile analysis. Instead of evaluating multiple IHC stains separately, the methylation pattern provides integrated tissue-of-origin information in one assay.
Solution Approach 2:
The methylation profile analysis serves multiple diagnostic functions simultaneously: it identifies tissue of origin, determines tumor classification, and provides prognostic information, replacing the need for multiple specialized IHC panels for different tumor types.
3Measurement precision
If imaging methods such as CT scans and PET scans are used to identify primary tumor, then the ability to resolve CUP cases improves to 30-50%, but the cost and exposure to radiation increase
Solution Approach 1:
The patent replaces physical imaging methods (CT, PET) with molecular analysis of tissue samples. Instead of using ionizing radiation to visualize tumors, the method uses DNA methylation profiling to identify tumor origin through biochemical analysis of extracted DNA.
4Adaptability or versatility
If methylation profiling is performed on FFPE tissues, then clinical applicability improves, but DNA degradation from formalin fixation occurs
Solution Approach 1:
The patent changes the molecular target from RNA to DNA, which is inherently more stable under formalin fixation conditions. DNA methylation patterns are preserved in FFPE tissues, allowing reliable profiling despite the harsh fixation process that would degrade RNA-based assays.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach predicts the tumor type with near 100% accuracy for CUP samples represented in the methylation fingerprint collection, providing insights into prognosis and treatment options, thereby improving treatment response and reducing unnecessary treatments and side effects.
Implementation Method 1
determining the methylation profile in a selected region of a DNA isolated from said CUP
Implementation Method 2
comparing the methylation profile of said selected region with the methylation profile of the same region in a DNA sample isolated from at least one primary tumor
Implementation Method 3
providing a substantial identity indicative of the tumor origin
Data Source
AI summary
The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patient suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.